Development of combination chemotherapy using NF-kappaB as molecular target for oral cancer
| Project/Area Number |
26861724
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
KANI Koichi 徳島大学, 病院, 助教 (60709583)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 臨床腫瘍学 |
|---|
| Outline of Final Research Achievements |
A marked antitumor effect was confirmed by using anti-cancer agent docetaxel and γ-tocotrienol of vitamin E in combination with oral cancer cell line B88 cells. In this study, we focused on NF-kappaB and examined it. That is, the combination of docetaxel and γ-tocotrienol suppressed NF-kappaB activity. Furthermore, it was thought that it induces apoptosis through inhibition of apoptosis inhibitory protein controlled by NF-kappaB and expression of apoptosis-related protein. Based on the findings obtained in this study, we would like to continue our research toward developing novel cancer chemotherapy.
|
Report
(4 results)
Research Products
(6 results)
